読み込み中
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
前日終値
$2.18
+$0.05 · +2.35%
日中の時刻はETです。市場データは遅延する場合があります。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日中レンジ
現在 $2.18
52週レンジ
現在 $2.18
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
9
著しい割高
センチメント
72
強気
リスク
56
やや高いリスク
モメンタム
90
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日中レンジ
現在 $2.18
52週レンジ
現在 $2.18
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 664.6万 USD | 1363.1万 USD | 6353.3万 USD | 9630万 USD | 5584.6万 USD |
| 売上原価 | 1290.1万 USD | 1.19億 USD | 1.57億 USD | 1375.8万 USD | 585万 USD |
| 粗利益 | −625.5万 USD | −1.05億 USD | −9365.4万 USD | 8254.2万 USD | 4999.6万 USD |
| 研究開発 | 1.08億 USD | 1.35億 USD | 1.73億 USD | 3.2億 USD | 2.16億 USD |
| 販売・一般管理 | 4652.1万 USD | 9063.9万 USD | 9685.7万 USD | 8423.2万 USD | 5732.1万 USD |
| 営業費用 | 1.41億 USD | 1.05億 USD | 9685.7万 USD | 3.91億 USD | 2.67億 USD |
| 受取利息 | 1105.2万 USD | 1728.8万 USD | 1718.6万 USD | 584.2万 USD | 130.9万 USD |
| 減価償却費と償却費 | 929.5万 USD | 1896.2万 USD | 1828.2万 USD | 1375.8万 USD | 585万 USD |
| 営業利益 | −1.48億 USD | −2.1億 USD | −1.91億 USD | −3.08億 USD | −2.17億 USD |
| 純利益 | −1.36億 USD | −1.86億 USD | −1.61億 USD | −2.82億 USD | −2.12億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.63
上昇余地（158.26%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI763.46万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF286.76万0.00%954億 USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA117.66万0.01%217.28億 USD0.03%$32.79+0.40%
iShares Micro-Cap ETFIWC76.43万0.06%13.17億 USD0.60%$183+0.11%
Vanguard Health Care ETFVHT67.94万0.00%220億 USD0.09%$319.01+1.64%
Invesco RAFI US 1500 Small-Mid ETFPRFZ52.99万0.02%26.52億 USD0.36%$53.16+0.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM40万0.34%1.17億 USD0.73%$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC31.48万0.01%30.82億 USD0.25%$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
